Rein Therapeutics (RNTX) Net Income (2016 - 2026)
Rein Therapeutics (RNTX) posted quarterly Net Income of -$5.5 million for Q1 2026, up 15.5% year-over-year from -$4.8 million in Q1 2025, and up 83.08% quarter-over-quarter from -$32.8 million in Q4 2025.
Rein Therapeutics (RNTX) Net Income (2016 - 2026) Analysis & Trends
Rein Therapeutics (RNTX) has reported Net Income for 11 consecutive years, with -$5.5 million the latest figure, recorded in Q1 2026.
- In Q1 2026, Net Income rose 15.5% year-over-year to -$5.5 million; the TTM figure through Mar 2026 stood at -$51.3 million (up 48.99% YoY), while the FY2025 annual figure was -$50.7 million, up 38.16% from the prior year.
- Net Income advanced to -$5.5 million in Q1 2026 per RNTX's latest filing, from -$32.8 million in the prior quarter.
- Across five years, Net Income topped out at -$2.0 million in Q3 2023 and bottomed at -$82.1 million in Q4 2022.
- Historically, Net Income has averaged -$18.1 million across 5 years, with a median of -$8.2 million in 2022.
- Annual changes were most pronounced in 2023 — Net Income jumped 75.69% — and 2024, when it plunged 469.13%.
- Rein Therapeutics' Net Income stood at -$82.1 million in 2022, then jumped by 68.58% to -$25.8 million in 2023, then sank by 183.93% to -$73.2 million in 2024, then surged by 55.22% to -$32.8 million in 2025, then jumped by 83.08% to -$5.5 million in 2026.
- Business Quant data shows RNTX's Net Income at -$5.5 million in Q1 2026, -$32.8 million in Q4 2025, and -$5.6 million in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Net Income (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn | 1.10 Bn |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn | 1.30 Bn |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn | 482.00 Mn |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn | -782.00 Mn |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn | 237.01 Mn |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn | 164.49 Mn |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn | -355.03 Mn |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn | -13.27 Mn |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - | 81.49 Mn |
| 10 | Rein Therapeutics | 55.49 Mn | 55.49 Mn | - | -6.55 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | -6.55 Mn |
| Mar 31, 2026 | -5.55 Mn |
| Dec 31, 2025 | -32.80 Mn |
| Sep 30, 2025 | -5.65 Mn |
| Jun 30, 2025 | -7.31 Mn |
| Mar 31, 2025 | -6.57 Mn |
| Dec 31, 2024 | -73.24 Mn |
| Sep 30, 2024 | -9.45 Mn |
| Jun 30, 2024 | -11.30 Mn |
| Mar 31, 2024 | -16.10 Mn |
| Dec 31, 2023 | -25.80 Mn |
| Sep 30, 2023 | -1.98 Mn |
| Jun 30, 2023 | -1.99 Mn |
| Mar 31, 2023 | -4.98 Mn |
| Dec 31, 2022 | -82.09 Mn |
| Sep 30, 2022 | -6.58 Mn |
| Jun 30, 2022 | -8.17 Mn |
| Mar 31, 2022 | -8.56 Mn |
| Dec 31, 2021 | -76.51 Mn |
| Sep 30, 2021 | -7.24 Mn |